Benefit from delayed 2nd Pfizer jab: study

By Alistair Smout
Updated May 14 2021 - 10:54am, first published 10:47am
A new study compares immune responses between a three-week and 12-week Pfizer dosing interval.
A new study compares immune responses between a three-week and 12-week Pfizer dosing interval.

Pfizer's COVID-19 vaccine generates antibody responses three-and-a-half times larger in older people when a second dose is delayed to 12 weeks after the first, a British study suggests.

Subscribe now for unlimited access.

$0/

(min cost $0)

or signup to continue reading

See subscription options

Get the latest Tenterfield news in your inbox

Sign up for our newsletter to stay up to date.

We care about the protection of your data. Read our Privacy Policy.